Real-life observations possess recently demonstrated considerably greater results with a share of responders ( 50% reduced amount of MMDs), ranging between your 48 and 53% following the third erenumab administration (15, 16)
Real-life observations possess recently demonstrated considerably greater results with a share of responders ( 50% reduced amount of MMDs), ranging between your 48 and 53% following the third erenumab administration…